Based on next-generation RNA sequencing data previously published by Hunter et al., the present list was derived from 131 genes affected by chromosome 6q deletions and 3103 genes associated with CXCR4 mutations. Log-2 fold change (LogFC) estimates are shown relative to both 6q deletions and CXCR4 mutations.
Waldenström's Macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by bone marrow (BM) infiltration of immunoglobulin M (IgM)-secreting lymphoplasmacytic cells.
1 Activating mutations in MYD88 are present in 93-97% of WM and 50-70% of IgM monoclonal gammopathy of undetermined significance (MGUS) patients.
2 IgM MGUS patients with MYD88 mutations may be at a higher risk of progression to WM.
3 Mutated MYD88 triggers WM cell growth and survival by activation of nuclear factor κ-light-chainenhancer of activated B cells (NF-κB) pro-survival signaling through interleukin-1 receptor-associated kinase 1 (IRAK1)/IRAK4 and Bruton's tyrosine kinase (BTK). WM patients with wild-type MYD88 (MYD88 WT ) show recurring somatic mutations in TBL1XR1, NFKB2, and the CARD11-BCL10-MALT1 (CBM) complex genes BCL10 and MALT1, and show shorter survival and a higher incidence of associated diffuse large B-cell lymphoma events versus MYD88 mutated (MYD88 MUT ) patients. 4 
MYD88
MUT WM patients also show higher levels of response and progression-free survival to ibrutinib in comparison to MYD88 WT patients. 5 Activating CXCR4 mutations are present in 30-40% of WM patients, and are typically subclonal to MYD88 mutations.
6 CXCR4 mutations trigger pro-survival protein kinase B (AKT) and extracellular signal-regulated kinase 1 (ERK1/2) signaling and are associated with inferior and/or delayed response to many WM therapeutics, including ibrutinib. 5, 7 Deletions in chromosome 6q (del6q) occur in about 50% of WM patients, and are associated with the transition from IgM-MGUS to WM. 8, 9 The functional role of del6q in this transition, and their relationship to MYD88 and CXCR4 mutations remain to be characterized. A minimal region of deletion (MDR) for 6q (6q14.1-6q27) in WM patients bearing the MYD88 mutation was previously reported by us, 9 and included many genes with important regulatory functions for BTK/B-cell receptor (IBTK), apoptosis (FOXO3), (BCL2 BCLAF1) and NF-kB (TNFAIP3, HIVEP2), signaling ( Figure 1A ). In the study herein, we sought to delineate the gene losses related to del6q in asymptomatic and symptomatic WM, as defined by The Second International Workshop on WM (IWWM-2) criteria, 1 and their association to MYD88 and CXCR4 mutations and signaling.
The Dana-Farber/Harvard Cancer Center (DF/HCC) Institutional Review Board approved this study and the samples were collected following informed consent. The study cohort included 33 untreated WM patients (21 males, 12 females). Patients had a median age of 62 (range: 35-91) years, BM involvement of 60% (range: 2.5-90%), serum IgM levels of 3,010 (range: 257-6910) mg/dl, and hemoglobin of 10.9 (range: 8.4-14.4) g/dl. MYD88 and CXCR4 mutations were assessed using allele-specific polymerase chain reaction (PCR) and Sanger sequencing as previously described. 6 All MYD88 mutations corresponded to p.Leu265Pro and were present in 25 (76%) patients, 11 (44%) of whom also carried CXCR4 activating mutations (CXCR4 MUT ). MUT patients. Likewise, no individual gene demonstrated significantly different deletion rates between these groups. Our findings are therefore consistent with previous studies indicating that del6q was indicative of WM, regardless of symptomatic status.
8,11
In MYD88
MUT WM patients, two distinct patterns of del6q were identified. One group was comprised of 8/20 (40%) patients and showed more clonal and contiguous losses spanning across all MDR genes, while a second group (12/20; 60%) had more focal and subclonal genes Figure 1B,C) MUT WM, Figure 1D ). The number of patients in the MYD88
MUT cohort harboring at least one deleted gene was similar between the CXCR4 MUT (9/11; 82%) and CXCR4 WT (11/14; 79%; P=NS) populations. Because the nature of these deletions differed significantly with clonal contiguous deletions being mutually exclusive of CXCR4 mutations, we used RT-PCR to investigate the effect of del6q and CXCR4
MUT on CXCR4 transcript levels, and observed no differences in expression (data not shown). To investigate further, we performed principal component analysis on previously published RNASeq data from 57 WM patients using 131 genes that are differentially expressed in the presence of del6q.
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This analysis not only stratified patients by del6q, but also by MYD88/CXCR4 genotypes (Figure 2A ) indicating that some of these genes are also modulated by MYD88/CXCR4 status. The 20 most influential genes from the rotation matrix are available for the first two component Online Supplementary Table S1 . Intersecting the gene lists associated with del6q and CXCR4
MUT revealed 19 overlapping genes, all of which change in the same direction in response to these somatic events ( Table 1) MUT RNASeq data ( Figure  2B ). This generated three distinct clusters that significantly stratified patients based on del6q (P<0.005) and CXCR4 MUT (P<0.001) status. In context with previous studies that supported the acquisition of CXCR4 MUT and del6q after MYD88 MUT , 6, 8, 11 these genes may play a critical role in WM clonal evolution.
Via quantitative RT-PCR, we sought to determine those study genes that were transcriptionally impacted by the presence of CNA in our study cohort. This analysis included all study samples and revealed that clonal deletions of IBTK, BCLAF1 and HIVEP2 significantly reduced the corresponding gene transcriptional levels in the eight clonally 6qdel versus all the other MYD88 MUT patients (P=0.03, P=0.01, P=0.01, respectively; Figure 2C ).
Inhibitor of Bruton tyrosine kinase (IBTK) is a negative regulator of BTK, which is located downstream of mutated MYD88 and triggers pro-survival NF-κB signaling in WM.
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The lack of IBTK deletions in MYD88
WT WM was notable as the BTK inhibitor ibrutinib shows poor activity in MYD88
WT WM patients, consistent with the notion that BTK is not essential for tumor survival in this patient population.
5 BCLAF1 plays a pro-apoptotic role in the interaction with pro-survival BCL2 protein family members.
13 Its decreased expression may contribute to the survival of WM cells, which universally express high levels of BCL2.
10
IBTK and BCLAF1 could potentially help delineate those patients who are suited for BTK-inhibitors and BCL-2 antagonist therapies. Moreover, the BCL-2 inhibitor venetoclax has shown significant activity in a phase I trial conducted in relapsed/refractory non-Hodgkin lymphoma patients, including WM, 14 and is currently under further investigation in relapsed/refractory WM. HIVEP2, which also showed decreased transcription levels in clonally deleted patients, blocks NF-κB nuclear signaling by binding to NF-κB consensus binding sites.
15 Surprisingly, FOXO3 and TNFAIP3, which are important regulators of apoptosis and NF-κB signaling, respectively, were not impacted transcriptionally. Therefore, IBTK, BCLAF1 and HIVEP2 may serve as particularly important determinants of disease progression. However, the limited number of patients enrolled in the study herein precluded any investigation into the prognostic or predictive role for the 6q MDR genes examined, and further efforts into clarifying their clinical significance are warranted.
In MYD88 mutated patients, fully clonal 6qdel and CXCR4 mutation status showed mutual exclusivity, suggesting shared roles for the two genomic events.
CXCR4
MUT was previously shown by us to downregulate tumor suppressors that are transcribed in response to mutated MYD88. 10 Indeed, herein we identified 19 genes co-regulated by 6qdel and CXCR4 mutation status, which may be involved in WM clonal evolution. In summary, our findings provide new insights into WM pathogenesis, including loss of key regulators of BTK, apoptosis, BCL2 and NF-κB signaling in asymptomatic and symptomatic WM patients, and shared regulatory signaling for MYD88 MUT 3, 4 Luca Arcaini, 5, 6 Marzia Varettoni, 5 Mario Cazzola, 5, 6 Steven P. Treon 1, 2 and Zachary R. Hunter
